Merck Q2 Vaccine Sales Top $1 Billion On Strength Of New Products
Executive Summary
Sales of Merck's vaccines, including the human papillomavirus vaccine Gardasil, the rotavirus vaccine Rotateq and the herpes zoster vaccine Zostavax, reached more than $1 billion, reflecting a 199 percent increase over the second quarter of 2006, the company reported July 23